Advertisement
Canada markets closed
  • S&P/TSX

    21,642.87
    -97.33 (-0.45%)
     
  • S&P 500

    5,051.41
    -10.41 (-0.21%)
     
  • DOW

    37,798.97
    +63.86 (+0.17%)
     
  • CAD/USD

    0.7233
    -0.0020 (-0.27%)
     
  • CRUDE OIL

    85.29
    -0.07 (-0.08%)
     
  • Bitcoin CAD

    88,132.99
    +350.88 (+0.40%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,400.90
    -6.90 (-0.29%)
     
  • RUSSELL 2000

    1,967.48
    -8.23 (-0.42%)
     
  • 10-Yr Bond

    4.6590
    +0.0310 (+0.67%)
     
  • NASDAQ futures

    17,906.25
    +25.00 (+0.14%)
     
  • VOLATILITY

    18.40
    -0.83 (-4.32%)
     
  • FTSE

    7,820.36
    -145.17 (-1.82%)
     
  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     
  • CAD/EUR

    0.6811
    -0.0013 (-0.19%)
     

RDInvesting Provides Investors with Free In-Depth Equity Reports on CSII, SPNC, TNDM and VOLC

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous s stock reports and market updates.

Cardiovascular Systems Inc. (NASDAQ:CSII - News) shares declined 0.09 percent to close at $34.19 a share Friday. The stock traded between $34.09 and $35.74 on volume of 331,761 shares traded. Analysts at Needham have recently initiated coverage on the company with a "strong buy" rating and a price target of $47.00. Shares of Cardiovascular Systems have fallen approximately 0.30 percent year-to-date.

Find out more about Cardiovascular Systems including full access to the free equity report at:
www.RDInvesting.com/CSII

The Spectranetics Corporation (NASDAQ:SPNC - News) shares declined 4.18 percent to close at $29.80 a share Friday. The stock traded between $29.78 and $31.94 on volume of 353,822 shares traded. Analysts at Needham have recently initiated coverage on the company with a "buy" rating and a price target of $35.00. Shares of Spectranetics have gained approximately 20.0 percent year-to-date.

ADVERTISEMENT

Find out more about Spectranetics including full access to the free equity report at:
www.RDInvesting.com/SPNC

Tandem Diabetes Care Inc. (NASDAQ:TNDM - News) shares declined 4.13 percent to close at $25.06 a share Friday. The stock traded between $24.55 and $26.76 on volume of 286,160 shares traded. Analysts at Sterne Agee have recently initiated coverage on the company with a "neutral" rating and a price target of $26.00. Shares of Tandem Diabetes Care have fallen approximately 3.0 percent year-to-date.

Find out more about Tandem Diabetes Care including full access to the free equity report at:
www.RDInvesting.com/TNDM

Volcano Corporation (NASDAQ:VOLC - News) shares declined 1.27 percent to close at $22.59 a share Friday. The stock traded between $22.43 and $22.92 on volume of 648,500 shares traded. Analysts at Needham have recently initiated coverage on the company with a "hold" rating. Shares of Volcano have gained approximately 3.0 percent year-to-date.

Find out more about Volcano including full access to the free equity report at:
www.RDInvesting.com/VOLC

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Research Driven Investing
info@rdinvesting.com